Stay updated with breaking news from I Mab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
I-Mab (NASDAQ:IMAB – Get Rating) had its price objective decreased by Needham & Company LLC from $33.00 to $24.00 in a research report sent to investors on Monday morning, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock. Other research analysts have also recently issued reports about the company. HC […]
I-Mab (NASDAQ:IMAB – Get Rating) had its target price trimmed by Piper Sandler from $30.00 to $25.00 in a research note released on Monday morning, The Fly reports. The firm currently has an overweight rating on the stock. Separately, HC Wainwright reduced their price target on shares of I-Mab from $45.00 to $25.00 and set […]
I-Mab (NASDAQ:IMAB – Get Rating) had its price objective trimmed by HC Wainwright from $45.00 to $25.00 in a research note published on Monday morning, The Fly reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for I-Mab’s Q1 2023 earnings at $0.00 EPS, Q2 2023 earnings at […]
I-Mab (NASDAQ:IMAB – Get Rating) had its target price cut by Needham & Company LLC from $33.00 to $24.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. IMAB has been the topic of a number of other research reports. HC Wainwright lowered their price […]
Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting...